| scholarly article | Q13442814 |
| P50 | author | Gordon B. Mills | Q28086262 |
| Gary G. Chiang | Q55130333 | ||
| P2093 | author name string | Zhi Hong Lu | |
| Stan Krajewski | |||
| Andrew Y Lee | |||
| Jeffrey M Arbeit | |||
| Raleigh D Kladney | |||
| Dong Fan | |||
| Jenny M Shao | |||
| Mark B Shvartsman | |||
| Mollianne M Murray | |||
| P2860 | cites work | PRAS40 is an insulin-regulated inhibitor of the mTORC1 protein kinase | Q24300915 |
| AMPK phosphorylation of raptor mediates a metabolic checkpoint | Q24329244 | ||
| Enhanced sensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. | Q27824772 | ||
| Suppression of Peutz-Jeghers polyposis by targeting mammalian target of rapamycin signaling | Q27851424 | ||
| Serine phosphorylation and maximal activation of STAT3 during CNTF signaling is mediated by the rapamycin target mTOR | Q28144113 | ||
| Defining the role of mTOR in cancer | Q28235431 | ||
| Current development of mTOR inhibitors as anticancer agents | Q28255366 | ||
| Upstream and downstream of mTOR | Q28277365 | ||
| mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt | Q29547767 | ||
| IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer | Q29614594 | ||
| Ras, PI(3)K and mTOR signalling controls tumour cell growth | Q29614734 | ||
| Insulin signalling to mTOR mediated by the Akt/PKB substrate PRAS40 | Q29617097 | ||
| An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinase activity in Pten+/- mice | Q33943166 | ||
| Expression of Bcl-2 family member Bid in normal and malignant tissues | Q34997430 | ||
| Induction of hypervascularity without leakage or inflammation in transgenic mice overexpressing hypoxia-inducible factor-1alpha | Q35081587 | ||
| Hypoxia-inducible factor-1 facilitates cervical cancer progression in human papillomavirus type 16 transgenic mice | Q35916052 | ||
| mTOR and cancer: reason for dancing at the crossroads? | Q36344439 | ||
| Inflammation and breast cancer. Balancing immune response: crosstalk between adaptive and innate immune cells during breast cancer progression | Q36393268 | ||
| HIF-1alpha regulates epithelial inflammation by cell autonomous NFkappaB activation and paracrine stromal remodeling | Q36508826 | ||
| mTOR pathway as a target in tissue hypertrophy. | Q36591617 | ||
| Humoral immunity, inflammation and cancer | Q36727285 | ||
| Aberrant Rheb-mediated mTORC1 activation and Pten haploinsufficiency are cooperative oncogenic events | Q36843531 | ||
| Tumorigenic activity and therapeutic inhibition of Rheb GTPase | Q36843535 | ||
| Inhibition of the mTORC1 pathway suppresses intestinal polyp formation and reduces mortality in ApcDelta716 mice | Q36869970 | ||
| Molecular mechanisms of head and neck cancer | Q37159537 | ||
| Image analysis algorithms for immunohistochemical assessment of cell death events and fibrosis in tissue sections | Q37234868 | ||
| Triple-negative/basal-like breast cancer: review | Q37352934 | ||
| Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis | Q37486563 | ||
| Stat3 links activated keratinocytes and immunocytes required for development of psoriasis in a novel transgenic mouse model | Q38333221 | ||
| TORC1 is essential for NF1-associated malignancies | Q40029605 | ||
| Dissecting the Akt/mammalian target of rapamycin signaling network: emerging results from the head and neck cancer tissue array initiative. | Q40177512 | ||
| Reverse phase protein array: validation of a novel proteomic technology and utility for analysis of primary leukemia specimens and hematopoietic stem cells | Q40220260 | ||
| mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF-1-dependent pathways | Q44905183 | ||
| gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. | Q53418407 | ||
| Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression | Q59565588 | ||
| TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer | Q73833118 | ||
| Activation of the mTOR signaling pathway in renal clear cell carcinoma | Q79426596 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | sirolimus | Q32089 |
| carcinogenesis | Q1637543 | ||
| overexpression | Q61643320 | ||
| P304 | page(s) | 3287-3298 | |
| P577 | publication date | 2010-04-13 | |
| P1433 | published in | Cancer Research | Q326097 |
| P1476 | title | Mammalian target of rapamycin activator RHEB is frequently overexpressed in human carcinomas and is critical and sufficient for skin epithelial carcinogenesis | |
| P478 | volume | 70 |
| Q47433075 | A Deregulated PI3K-AKT Signaling Pathway in Patients with Colorectal Cancer. |
| Q38122226 | Adaptation to chronic mTOR inhibition in cancer and in aging. |
| Q27675096 | Arl2-GTP and Arl3-GTP regulate a GDI-like transport system for farnesylated cargo |
| Q39308756 | Down-regulation of miR-124/-214 in cutaneous squamous cell carcinoma mediates abnormal cell proliferation via the induction of ERK. |
| Q36029673 | Effect of Combined Treatment with Ursolic Acid and Resveratrol on Skin Tumor Promotion by 12-O-Tetradecanoylphorbol-13-Acetate |
| Q37269368 | Fas-associated protein with death domain (FADD) regulates autophagy through promoting the expression of Ras homolog enriched in brain (Rheb) in human breast adenocarcinoma cells |
| Q37459239 | Hyperactivation of mammalian target of rapamycin complex 1 (mTORC1) promotes breast cancer progression through enhancing glucose starvation-induced autophagy and Akt signaling |
| Q51037580 | Influence of Rictor and Raptor Expression of mTOR Signaling on Long-Term Outcomes of Patients with Hepatocellular Carcinoma. |
| Q42809090 | Inhibition of MAPK pathway is essential for suppressing Rheb-Y35N driven tumor growth |
| Q36456697 | Inhibition of mTOR suppresses UVB-induced keratinocyte proliferation and survival. |
| Q35027222 | Mammalian target of rapamycin and head and neck squamous cell carcinoma |
| Q50140280 | Overexpression of RHEB is associated with metastasis and poor prognosis in hepatocellular carcinoma |
| Q38223953 | Phytochemical modulation of the Akt/mTOR pathway and its potential use in cutaneous disease |
| Q39019763 | Pten loss induces autocrine FGF signaling to promote skin tumorigenesis |
| Q47569033 | RHEB1 expression in embryonic and postnatal mouse |
| Q27317214 | Rapamycin Promotes Mouse 4T1 Tumor Metastasis that Can Be Reversed by a Dendritic Cell-Based Vaccine |
| Q35106935 | Rapamycin and mTORC1 inhibition in the mouse: skin cancer prevention |
| Q33705425 | Rapamycin is a potent inhibitor of skin tumor promotion by 12-O-tetradecanoylphorbol-13-acetate |
| Q34051183 | Recent progress in the study of the Rheb family GTPases. |
| Q56603206 | Resetting the epigenetic balance of Polycomb and COMPASS function at enhancers for cancer therapy |
| Q35944443 | Rheb phosphorylation is involved in p38-regulated/activated protein kinase-mediated tumor suppression in liver cancer. |
| Q38559263 | Rheb signaling and tumorigenesis: mTORC1 and new horizons |
| Q37865381 | Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. |
| Q40751673 | Targeting nuclear factor-kappa B to overcome resistance to chemotherapy. |
| Q37872655 | Targeting phosphatidylinositol 3 kinase (PI3K)-Akt beyond rapalogs |
| Q34173253 | Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway |
| Q26800216 | The PI3K/AKT Pathway and Renal Cell Carcinoma |
| Q39297991 | The mTOR inhibitor rapamycin opposes carcinogenic changes to epidermal Akt1/PKBα isoform signaling. |
| Q24627306 | The mTOR signalling pathway in human cancer |
| Q35216878 | The mammalian target of rapamycin regulates cholesterol biosynthetic gene expression and exhibits a rapamycin-resistant transcriptional profile. |
| Q37837732 | Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. |
| Q92335740 | Transcriptomic changes during TGF-β-mediated differentiation of airway fibroblasts to myofibroblasts |
| Q34092485 | Transient mTOR inhibition facilitates continuous growth of liver tumors by modulating the maintenance of CD133+ cell populations |
| Q34724225 | Tuberous Sclerosis Complex 1: An Epithelial Tumor Suppressor Essential to Prevent Spontaneous Prostate Cancer in Aged Mice |
| Q44547715 | Tumor and transplantation |
| Q64883325 | Unfolded Protein Response (UPR) in Survival, Dormancy, Immunosuppression, Metastasis, and Treatments of Cancer Cells. |
| Q28078957 | Will targeting PI3K/Akt/mTOR signaling work in hematopoietic malignancies? |
| Q33685931 | ZEB1 sensitizes lung adenocarcinoma to metastasis suppression by PI3K antagonism |
| Q27007511 | mTOR Signaling in Protein Translation Regulation: Implications in Cancer Genesis and Therapeutic Interventions |
| Q38590634 | mTOR in health and in sickness |
| Q28252695 | mTOR signaling in tumorigenesis |
| Q47748656 | mTORC1 loss impairs epidermal adhesion via TGF-β/Rho kinase activation |
| Q39501076 | mTORC1 signaling in primary central nervous system lymphoma. |
Search more.